Skip to main content

Hofseth Biocare ASA: HBC AQUIRES A 34 PERCENT STAKE IN HEALTHCARE AND PETCARE DISTRIBUTOR ATLANTIC DELIGHTS LTD FOR ACCESS TO CHINESE MARKET

Written by Customer Service on . Posted in Public Companies.

Hofseth BioCare ASA (“HBC”), today announces the completion of a purchase of 34 % stake in Hong Kong and China based finished products distributor Atlantic Delights Ltd (“AD”). Over the last five years, AD has established an impressive business of marketing and distributing dietary supplements and nutritional products, based on marine ingredients, in the Asia-Pacific region, including China.HBC pays approx. USD 700,000 for a 34 % stake in AD and with that ownership, obtains an import license and distribution license in China which would otherwise be very difficult to attain. HBC and AD have already started to merge sales teams to improve and increase distribution reach and achieve other synergies in the Asia Pacific markets.  The registration process for the distribution of all other finished products for human nutrition from HBC has also begun and is expected to be approved shortly.“As our most valued customer in China, we have now taken the opportunity to take direct ownership in their business to help grow their sales and distribution strategy. HBC will now leverage AD’s existing import and distribution licenses that would otherwise be difficult to attain as outsiders, so this gives us a direct option at taking advantage of the phenomenal opportunity with the Chinese pet care market.  China is currently our largest market for Brilliant salmon oil, and we expect its growth to accelerate further from here. All other finished products will also be able to be distributed using this domestic entity going forward which represents another untapped opportunity for us,” says CEO Roger Hofseth of Hofseth BioCare.The acquisition comes at an exciting time for HBC with Brilliant Salmon Oil™ in particular having phenomenal success in multiple markets and already beating internal company expectations for 2020 with multiple platform launches in Europe and the US and through several distributors covering most of North America. Brilliant Salmon Oil is now the best-selling finished product from HBC.The last 3 years, AD has a sales CAGR of 330 % and we expect growth to accelerate in the next few years when they join forces with HBC’s existing sales team and as they include other products from HBC into their product range.For further information, please contact:
Roger Hofseth, CEO of Hofseth BioCare ASA
Phone: +47 951 47 941
E-mail: rh@hofseth-as.noAbout Hofseth BioCare ASA:
HBC is a Norwegian biotech company that develops high-value ingredients and finished products. The ingredients are in various stages of discovery and preclinical development in collaboration with multiple clinics and university research labs in several countries. Lead preclinical and clinical candidates are in development toward treatment for iron-deficiency anemia, Gastro-Intestinal Inflammation (NEC/IBS/UC), prediabetes, age-related sarcopenia and osteoarthritis.The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC can preserve the quality of lipids, proteins and calcium from fresh salmon off-cuts. Hofseth BioCare’s headquarters are in Ålesund, Norway with branches in Oslo, London, Zürich, Chicago, Menlo Park and Tokyo.This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.